Displaying all 16 publications

Abstract:
Sort:
  1. Shabil M, Gaidhane AM, Vadia N, Menon SV, Chennakesavulu K, Panigrahi R, et al.
    BMC Neurol, 2025 Feb 21;25(1):71.
    PMID: 39984906 DOI: 10.1186/s12883-025-04083-x
    BACKGROUND: Hydrocarbon exposure, including polycyclic aromatic hydrocarbons (PAHs) and volatile organic compounds (VOCs), is increasingly linked to vascular dysfunction and stroke, a leading cause of morbidity and mortality globally. Common in occupational and environmental contexts, hydrocarbons induce oxidative stress, systemic inflammation, and endothelial dysfunction, disrupting vascular health. This systematic review examines the association between hydrocarbon exposure and stroke, emphasizing specific metabolites and their cerebrovascular effects.

    METHODS: A comprehensive search across PubMed, Embase, and Web of Science was conducted through December 10 2024, identifying observational studies exploring hydrocarbon exposure and stroke risk. Studies meeting predefined inclusion criteria, excluding those with major methodological flaws, were synthesized narratively. Variations in hydrocarbon types, population demographics, and stroke outcomes were considered.

    RESULTS: Six studies, including five cross-sectional and one retrospective cohort, with sample sizes ranging from 5,537 to 283,666 participants, demonstrated significant associations between hydrocarbon exposure and stroke risk. Key findings revealed strong associations for metabolites like 1-hydroxynaphthalene (OR: 1.89; 95% CI: 1.62-2.20) and 2-hydroxyfluorene (OR: 1.94; 95% CI: 1.66-2.26). However, variability in findings was noted, attributed to differences in study design, exposure levels, and populations studied.

    CONCLUSION: This review highlights a complex relationship between hydrocarbon exposure and stroke risk, with some studies indicating significant associations and others reporting inconsistencies. Standardized, large-scale research is essential to clarify this relationship, identify high-risk populations, and guide public health strategies to mitigate exposure and prevent stroke.

    CLINICAL TRIAL NUMBER: Not applicable.

  2. Shabil M, Gaidhane AM, Vadia N, Menon SV, Chennakesavulu K, Panigrahi R, et al.
    Eur J Obstet Gynecol Reprod Biol, 2025 Apr 17;308:214-221.
    PMID: 40086257 DOI: 10.1016/j.ejogrb.2025.03.012
    BACKGROUND: Maternal hypertensive disorders (HDP) remain a major contributor to maternal and perinatal morbidity and mortality worldwide, particularly in South Asia, where healthcare disparities persist.

    OBJECTIVE: This study aims to analyze trends in maternal hypertensive disorders across South Asia from 1990 to 2021, leveraging data from the Global Burden of Disease (GBD) study to evaluate the effectiveness of healthcare interventions and provide actionable recommendations.

    METHODS: We conducted a retrospective analysis using GBD 2021 data for Bangladesh, Bhutan, India, Nepal, and Pakistan. Health trends such as prevalence, incidence, and maternal mortality ratios (MMR) were analyzed using descriptive statistics and Join point regression. This approach allowed us to identify significant changes and trends over the studied period.

    RESULTS: The study revealed significant declines in the prevalence and MMR associated with maternal hypertensive disorders across the region. Notable reductions were observed in Bangladesh, Bhutan, India, and Nepal, while Pakistan showed minimal improvement, indicating ongoing healthcare challenges. The analysis underscores substantial regional disparities, particularly in Pakistan, which reported higher prevalence rates and MMR across all age groups.

    CONCLUSIONS: The findings suggest that targeted healthcare interventions can effectively reduce the burden of maternal hypertensive disorders in South Asia. However, persistent disparities in Pakistan highlight the need for region-specific strategies to address gaps in healthcare access and quality. Strengthening healthcare policies and improving intervention coverage could further mitigate the burden of HDP in South Asia.

  3. Bushi G, Khatib MN, Balaraman AK, Ballal S, Bansal P, Tomar BS, et al.
    BMC Public Health, 2024 Nov 18;24(1):3200.
    PMID: 39558300 DOI: 10.1186/s12889-024-20746-9
    BACKGROUND: As e-cigarettes gain popularity as potential tobacco cessation aids, concerns arise about their dual use with traditional cigarettes, especially among pregnant women, potentially subjecting both women and fetuses to heightened risks. This systematic review and meta-analysis aimed to determine the overall prevalence of dual use of tobacco smoking and e-cigarette use in pregnant women.

    METHODS: A literature search was conducted across databases including PubMed, Embase, Web of Science, and Cochrane on October 20, 2023. The included studies reported the number of pregnant women and the count of those who were dual users. Quality assessment was undertaken using the JBI tool. The pooled prevalence of dual use was determined via a random-effects model. All statistical analyses were executed using R software, version 4.3.

    PROSPERO: CRD42023486020.

    RESULTS: Eighteen studies were analyzed, encompassing 5,983,363 pregnant women. The meta-analysis indicated an overall prevalence of 4.6% (95% CI: 2.0-10.3) for dual users with significant heterogeneity (I2 = 100%). Subgroup analysis based on the country showed a prevalence of 4.9% (95% CI: 2.0 to 11.6) for USA and 8.1% (95% CI: 0.00 to 1.00) for UK. Meta-regression revealed reduction of prevalence of dual use from 2019 to 2023. A potential publication bias was indicated by the LFK index and the Doi plot.

    CONCLUSION: The dual consumption of e-cigarettes and traditional tobacco in pregnant women is a significant health concern, with a notable prevalence. Given the established risks of tobacco smoking during pregnancy and the uncertainties surrounding e-cigarettes, more comprehensive research and public health interventions are urgently needed to address this issue.

  4. Kumar V, Zahiruddin QS, Jena D, R R, Kaur M, Srivastava M, et al.
    Expert Rev Endocrinol Metab, 2025 Jan;20(1):99-106.
    PMID: 39763434 DOI: 10.1080/17446651.2024.2448790
    BACKGROUND: The rapid rise of non-communicable diseases, particularly type 2 diabetes mellitus (T2DM), poses a significant global public health challenge, with South Asia experiencing an increasingly severe burden. This study aimed to analyse historical trends of T2DM across South Asia from 1990 to 2021 and forecast incidence through 2031.

    RESEARCH DESIGN AND METHODS: We carried out analysis based on the data from the 2021 Global burden of disease study. Joinpoint regression was used to identify significant changes in trends over time, and ARIMA models were applied to forecast incidence rates.

    RESULTS: Between 1990 and 2021, the average annual percentage change (AAPC) of age-standardized prevalence rates and incidence rates increased by 2.15 and 1.72 respectively. The age-standardized mortality rate rose more slowly, at 1.05 AAPC, with females experiencing a slightly higher AAPC than males. ARIMA forecasts suggest that by 2031, T2DM incidence rates will continue to rise significantly across all South Asian countries.

    CONCLUSIONS: This study highlights the need for public health policies focused on preventing obesity, promoting physical activity, and improving healthcare access. It also calls for addressing regional disparities in T2DM prevalence and mortality to better allocate resources and prioritize policies to combat the diabetes epidemic inSouth Asia.

  5. Tiwari S, Khatib MN, Mm R, Kaur M, Sharma GC, Sudan P, et al.
    BMC Infect Dis, 2025 Jan 24;25(1):111.
    PMID: 39856559 DOI: 10.1186/s12879-025-10498-1
    BACKGROUND: Dengue and leptospirosis are prominent vector-borne diseases in tropical and subtropical regions, sharing overlapping geographic distribution and clinical presentations, which complicates diagnosis and management. Co-infection of these pathogens places additional strain on healthcare resources in endemic areas. This study aims to systematically estimate the prevalence and mortality rates of dengue and leptospirosis co-infections and assess their clinical implications.

    METHODS: Adhering the PRISMA 2020 guidelines and registered in the PROSPERO database, we conducted a systematic review and meta-analysis using the PubMed, Embase, and Web of Science databases up to October 2024. Nested Knowledge was used for screening and data extraction. Studies reporting quantitative data on the prevalence or mortality of dengue and leptospirosis co-infections were included. Data extraction and quality assessment were performed independently by two reviewers using the Modified Newcastle-Ottawa Scale. Statistical analyses, including prevalence and mortality estimation, sensitivity analysis were conducted using R, with heterogeneity evaluated by the I² statistic.

    RESULTS: Out of 3,982 records, 14 studies met the eligibility criteria, yielding a pooled prevalence of dengue and leptospirosis co-infection at 2.33% (95% CI: 1.41-3.46%) across 16,638 participants, with significant heterogeneity (I² = 90%). The prediction interval for co-infection ranged from 0.05 to 7.27%. The pooled mortality rate among co-infected patients was 9.96% (95% CI: 0-53.49%), with moderate heterogeneity (I² = 71%). The prediction interval for mortality ranged from 0.00 to 100%. Publication bias was indicated by an LFK index of 2.52.

    CONCLUSION: This meta-analysis revealed a moderate prevalence and a notable mortality rate for dengue and leptospirosis co-infections, with significant variability observed across different studies. Further research into the immunopathology and the implementation of integrated surveillance systems could enhance the effectiveness of diagnosis and treatment strategies in regions where these diseases are endemic.

  6. Malvi A, Khatib MN, Balaraman AK, Roopashree R, Kaur M, Srivastava M, et al.
    BMC Pulm Med, 2025 Jan 29;25(1):48.
    PMID: 39881272 DOI: 10.1186/s12890-025-03516-0
    BACKGROUND: Cannabis is the third most widely used psychoactive substance globally, and its consumption has been increasing, particularly with the growing trend of legalization for medicinal and recreational use. Recent studies have raised concerns about the potential impact of cannabis on respiratory health, specifically the risk of asthma, a significant public health concern. This systematic review aimed to consolidate research on the association between cannabis use and the risk of asthma.

    METHODS: A comprehensive search was conducted across PubMed, Embase, and Web of Science, covering studies published up to September 30, 2024. We included peer-reviewed observational studies evaluating the link between cannabis consumption and the risk of asthma diagnosis. Data synthesis employed a random-effects meta-analysis to account for heterogeneity. R statistical software (version 4.4) was used for statistical analyses.

    RESULTS: The search yielded 8 relevant studies after screening 1,887 records. The pooled odds ratio (OR) for the association between cannabis consumption and the risk of asthma diagnosis was 1.31, 95% confidence interval (CI): 1.19-1.44, indicating greater odds of having asthma compared to non-users. Moderate heterogeneity was observed (I² = 46%), and sensitivity analysis confirmed the robustness of the findings.

    CONCLUSION: This systematic review and meta-analysis identifies a significant association between cannabis use and greater odds of having asthma. These findings emphasize the importance of raising awareness about the potential respiratory risks associated with cannabis use. Future research should prioritize identifying moderating factors, such as the frequency and mode of cannabis consumption, to enhance understanding of this association and provide a stronger evidence base for potential public health interventions.

    CLINICAL TRIAL NUMBER: Not applicable.

  7. Kumar V, Singh M, Khatib MN, Balaraman AK, Roopashree R, Kaur M, et al.
    Expert Rev Respir Med, 2025 Feb 12.
    PMID: 39917855 DOI: 10.1080/17476348.2025.2464882
    BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally, particularly in low- and middle-income countries like India. This study aims to analyze regional trends and project future burden of COPD in India using data from the Global Burden of Disease (GBD) 1990-2021.

    METHODS: This analysis utilized data from the GBD study to assess age-standardized prevalence (ASPR), incidence (ASIR), disability-adjusted life years (DALYs) (ASDR), and mortality rates (ASMR) for COPD across Indian states. Joinpoint regression was used to analyze temporal trends, while ARIMA models predicted future incidence rates.

    RESULTS: In 2021, the highest ASIR was observed in Rajasthan at 306.28, and the highest ASMR was observed in Uttarakhand at 227.19. Projections suggest that the ASIR for COPD in India will decrease from 265.16 in 2022 to 258.19 by 2031. The heatmap analysis identified states like Uttarakhand and Rajasthan as having the highest DALYs attributable to COPD risk factors, including air pollution and tobacco use.

    CONCLUSION: COPD remains a public health challenge in India, with regional variability. Targeted interventions addressing air pollution, smoking cessation, and improved healthcare access are essential to mitigate the disease's future burden, particularly in high-risk regions.

  8. Shabil M, Khatib MN, Ballal S, Bansal P, Tomar BS, Ashraf A, et al.
    J Med Virol, 2024 Dec;96(12):e70122.
    PMID: 39707867 DOI: 10.1002/jmv.70122
    Mpox, formerly known as monkeypox, has re-emerged as a significant global health concern, particularly during the widespread outbreak of 2022. As an orthopoxvirus related to the eradicated smallpox virus, mpox has been primarily managed with smallpox vaccines and treatments, including the antiviral agent Tecovirimat. This systematic review aims to evaluate the effectiveness and safety of Tecovirimat in treating mpox, focusing on its use during the 2022 outbreak, especially among high-risk populations, including men who have sex with men and people living with HIV. We conducted a comprehensive search across databases, such as Embase, PubMed, and Web of Science, up to August 30, 2024. The selection involved a two-stage review process utilizing the Nested Knowledge platform, which helped streamline the screening and data extraction. We included studies that focused on the clinical efficacy and safety of Tecovirimat in human patients with confirmed mpox infections. Our analysis mainly synthesized data narratively due to the heterogeneity of study designs and outcomes. Fifteen studies met the inclusion criteria, providing data on 1031 mpox cases. The preliminary analysis of the PALM 007 RCT indicated that tecovirimat did not significantly outperform placebo in lesion resolution for all patients. Lesions healed faster than expected, regardless of tecovirimat or placebo treatment. A lower mortality rate of 1.7% among those enrolled in the PALM 007 RCT was observed, compared to the general mpox mortality rate of 3.6% or higher in the DRC. Observational studies revealed that early administration of Tecovirimat, especially within the first week of symptom onset, significantly improves symptom resolution, reduces the severity of the disease, and decreases the likelihood of hospitalization and complications in observational studies. However, the impact on viral clearance was inconsistent, and some studies suggested limited efficacy in severely immunocompromised patients. Regarding safety, Tecovirimat was generally well-tolerated as indicated by the RCT; however, mild adverse effects such as fatigue, headache, and nausea were commonly reported among observational studies. Serious adverse events were rare but included elevated liver enzymes and psychiatric symptoms, particularly in patients with pre-existing conditions. Tecovirimat demonstrates some potential benefits in treating mpox, particularly when administered early. The PALM 007 RCT failed to meet the efficacy point. Tecovirimat is generally well-tolerated with a favorable safety profile, although monitoring is advisable for those with existing liver or renal conditions. Despite promising results, further large-scale randomized controlled trials are needed to fully ascertain the drug's effectiveness across diverse populations and to explore its impact on viral clearance and transmission dynamics.
  9. Sharma N, Khatib MN, Balaraman AK, Roopashree R, Kaur M, Srivastava M, et al.
    Int Urol Nephrol, 2025 Apr;57(4):1039-1049.
    PMID: 39495435 DOI: 10.1007/s11255-024-04266-4
    BACKGROUND: Prostate cancer is one of the most prevalent malignancies among men globally. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), primarily used for type 2 diabetes mellitus (T2DM) management, have been investigated for their potential effects on cancer risks. This systematic review and meta-analysis aimed to assess the association between GLP-1 RA use and risk reduction of prostate cancer.

    METHODS: A comprehensive literature search was conducted across PubMed, Embase, and Web of Science up to July 30, 2024. Studies that met the inclusion criteria randomized controlled trials, cohort studies, case-control studies, and observational studies assessing the incidence of prostate cancer in GLP-1 RA-treated patients were included. The quality of studies was evaluated using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias tool. Meta-analysis was performed using a random effects model.

    RESULTS: A total of five studies were included, analyzing data from diverse international contexts. The included studies showed a reduced risk of prostate cancer with both adjusted and unadjusted effect estimates with GLP-1 RAs. The meta-analysis revealed an RR of 0.72 (95% CI: 0.610 to 0.832), indicating a statistically significant 28% reduction in prostate cancer risk associated with GLP-1 RA use compared to placebo or other antidiabetic drugs. Moderate heterogeneity was observed (I2 = 51%). Sensitivity analysis confirmed the results.

    CONCLUSION: The findings suggest a significant protective association between GLP-1 RA use and reduced prostate cancer risk in men, particularly those with T2DM. This supports the potential of GLP-1 RAs not only in diabetes management but also as a strategy to mitigate cancer risk. Further research is required to confirm these findings and explore the underlying mechanisms, considering different dosages, durations of therapy, and patient subgroups based on demographic and metabolic characteristics.

  10. Khan Z, Gaidhane AM, Singh M, Ganesan S, Kaur M, Sharma GC, et al.
    Am J Ophthalmol, 2025 Feb 20;273:192-204.
    PMID: 39986640 DOI: 10.1016/j.ajo.2025.02.022
    PURPOSE: Diabetic retinopathy (DR) is a leading cause of vision loss worldwide, making early detection critical to prevent blindness. IDX-DR, an FDA-approved autonomous artificial intelligence (AI) system, has emerged as an innovative solution to improve access to DR screening. This systematic review and meta-analysis aimed to evaluate the diagnostic accuracy of IDX-DR in detecting diabetic retinopathy.

    DESIGN: Systematic review and meta-analysis.

    METHODS: A comprehensive literature search was conducted across PubMed, Embase, Scopus and Web of Science, identifying studies published through October 5, 2024. Studies involving adult patients with Type 1 or Type 2 diabetes and reporting diagnostic metrics such as sensitivity and specificity were included. The primary outcomes were pooled sensitivity and specificity of IDX-DR. A bivariate random-effects model was used for meta-analysis, and summary receiver operating characteristic (SROC) curves were generated to assess diagnostic performance. Statistical analyses were performed using MetaDisc software version 2.0.

    RESULTS: Thirteen studies involving 13,233 participants met the inclusion criteria. IDX-DR's pooled sensitivity was 0.95 (95% CI: 0.82-0.99), and its pooled specificity was 0.91 (95% CI: 0.84-0.95). The SROC curve confirmed IDX-DR's high diagnostic accuracy in detecting diabetic retinopathy across various clinical environments. The AUC value of 0.95 demonstrated high sensitivity and specificity, indicating a robust diagnostic performance for IDX-DR in detecting diabetic retinopathy.

    CONCLUSION: IDX-DR is a highly effective diagnostic tool for diabetic retinopathy screening, with robust sensitivity and good specificity. Its integration into clinical practice, especially in resource-limited settings, can potentially improve early detection and reduce vision loss. However, careful implementation is needed to address challenges such as over-diagnosis and ensure the tool complements clinical judgment. Future studies should explore the long-term impacts of AI-based screening and address ethical considerations surrounding its use.

  11. Soni M, Khatib MN, Balaraman AK, Roopashree R, Kaur M, Srivastava M, et al.
    J Epidemiol Glob Health, 2025 Mar 13;15(1):43.
    PMID: 40080234 DOI: 10.1007/s44197-025-00359-0
    BACKGROUND: Neonatal disorders represent a significant public health challenge, particularly in low- and middle-income countries, where they account for 79% of global neonatal mortality. South Asia, comprising countries such as India, Pakistan, Bangladesh, Nepal, and Bhutan, bears a disproportionately high burden, contributing to 38% of the world's neonatal deaths. Despite notable progress, South Asia remains off track in meeting the Sustainable development goals (SDG). This study aims to assess the current burden, trends in neonatal disorders, and forecast mortality rates across South Asian countries, providing insights to guide investment priorities and improve neonatal outcomes.

    METHODS: Data for this study were sourced from the Global burden of disease (GBD) 2021 study, which utilizes a Bayesian meta-regression model to estimate mortality, prevalence, and disability-adjusted life years (DALYs). Spatial maps depicting the age-standardized prevalence rate and age-standardized mortality rate for neonatal disorders in South Asia were generated using QGIS software. Mortality forecasts for the period 2022-2031, attributed to various neonatal disorders, were produced employing the Auto-Regressive Integrated Moving Average model in R software. Additionally, an analysis of overall neonatal mortality trends from 1980 to 2021 was conducted, supplemented by a heat map that compares DALYs attributable to various neonatal disorders across South Asian countries in 2021.

    RESULTS: Between 1980 and 2021, South Asia experienced a substantial decline in neonatal mortality rates, with India and Bangladesh leading the progress. Mortality decreased by 40%, while DALYs fell by 35%, despite a 15% increase in the prevalence. The prevalence of neonatal encephalopathy due to birth asphyxia and trauma surged by 355%, yet its mortality dropped by 31%. Pakistan recorded the highest neonatal mortality and disease burden, particularly for hemolytic disease and other neonatal jaundice and neonatal encephalopathy due to birth asphyxia and trauma. In India and Bangladesh, neonatal preterm birth and neonatal sepsis and other neonatal infections contributed most to mortality. Neonatal encephalopathy due to birth asphyxia and trauma accounted for the highest DALYs. Forecasts predict continued reductions in neonatal mortality across South Asia, except in Pakistan, where persistently high rates are expected till 2031.

    CONCLUSION: For South Asian countries to meet the SDG target for neonatal mortality by 2030, intensified and continuous efforts are required. These efforts should focus on identifying high-risk pregnancies and improving the quality of care during childbirth to address the root causes and reduce preventable neonatal deaths.

  12. Kumar V, Jena D, Zahiruddin QS, Roopashree R, Kaur M, Srivastava M, et al.
    Int J Urol, 2025 Mar;32(3):277-284.
    PMID: 39670291 DOI: 10.1111/iju.15641
    OBJECTIVES: The objectives of this study were to analyze trends in prostate cancer incidence, incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021 via data from the Global Burden of Disease (GBD) study in South Asia. Additionally, the study projects future prostate cancer incidence rates up to 2031 to inform public health interventions in South Asia.

    METHODS: Data covering South Asian countries such as Bangladesh, Bhutan, India, Nepal, and Pakistan were obtained from the GBD 2021 portal. Age-standardized rates (ASRs) for prostate cancer metrics, including incidence (ASIR), prevalence (ASPR), mortality (ASMR), and DALYs (ASDR), were analyzed via joinpoint and ARIMA modeling techniques. Geographic variations in ASRs were mapped via QGIS software.

    RESULTS: The prostate cancer ASIR, ASPR, and ASDR significantly increased from 1990 to 2021, particularly among individuals aged 60-65 years. The highest incidence and mortality rates were observed in Pakistan. The total percentage change in incidence in India was the highest at 61%. Projections indicate a continued rise in prostate cancer incidence, with South Asia's ASIR expected to reach 9.34 per 100 000 by 2031.

    CONCLUSIONS: The growing burden of prostate cancer in South Asia highlights the need for enhanced screening programs, public awareness, and healthcare infrastructure improvements. Without intervention, the increasing incidence and mortality rates could strain healthcare resources, emphasizing the urgency of region-specific public health strategies.

  13. Singh P, Khatib MN, R R, Kaur M, Srivastava M, Barwal A, et al.
    Oncol Rev, 2025;19:1541326.
    PMID: 40160263 DOI: 10.3389/or.2025.1541326
    Advancements in personalized neoantigen-based cancer vaccines are ushering in a new era in oncology, targeting unique genetic alterations within tumors to enhance treatment precision and efficacy. Neoantigens, specific to cancer cells and absent in normal tissues, are at the heart of these vaccines, promising to direct the immune system specifically against the tumor, thereby maximizing therapeutic efficacy while minimizing side effects. The identification of neoantigens through genomic and proteomic technologies is central to developing these vaccines, allowing for the precise mapping of a tumor's mutational landscape. Despite advancements, accurately predicting which neoantigens will elicit strong immune responses remains challenging due to tumor variability and the complexity of immune system interactions. This necessitates further refinement of bioinformatics tools and predictive models. Moreover, the efficacy of these vaccines heavily depends on innovative delivery methods that enhance neoantigen presentation to the immune system. Techniques like encapsulating neoantigens in lipid nanoparticles and using viral vectors are critical for improving vaccine stability and delivery. Additionally, these vaccines contribute towards achieving Sustainable Development Goal 3.8, promoting universal health coverage by advancing access to safe and effective cancer treatments. This review delves into the potential of neoantigen-based vaccines to transform cancer treatment, examining both revolutionary advancements and the ongoing challenges they face.
  14. Akashanand, Khatib MN, Balaraman AK, Roopashree R, Kaur M, Srivastava M, et al.
    J Asthma, 2025 Jun;62(6):1020-1031.
    PMID: 39817407 DOI: 10.1080/02770903.2025.2453810
    OBJECTIVE: Asthma poses a significant health burden in South Asia, with increasing incidence and mortality despite a global decline in age-standardized prevalence rates. This study aims to analyze asthma trends from 1990 to 2021, focusing on prevalence, incidence, mortality, and disability-adjusted life years (DALYs) across South Asia. The study also assesses the impact of risk factors like high body mass index (BMI), smoking, and occupational exposures on asthma outcomes.

    METHOD: We extracted asthma data from the Global Burden of Disease database for South Asia (1990-2021). Joinpoint regression analysis was used to assess temporal trends in asthma burden. Total Percentage change (TPC) in age-standardized rates of incidence, mortality, and DALYs were calculated. Data were stratified by gender, and the contribution of risk factors was evaluated.

    RESULTS: Asthma-related mortality in South Asia decreased by 37%, from 27.78 per 100,000 (1990) to 17.54 per 100,000 (2021). The Maldives showed the most significant reduction in mortality (78.31%), while Bangladesh recorded a 47.44% reduction in prevalence and a 62.64% decrease in DALYs. High BMI, smoking, and environmental risks contributed significantly to DALYs, with environmental factors playing a major role in countries like Afghanistan (20.73%) and Bhutan (18.58%). Females, particularly those over 20, experienced higher asthma-related DALYs than males.

    CONCLUSION: Asthma burden in South Asia has reduced over the past three decades, yet the absolute number of cases continues to rise, driven by population growth and environmental risk factors. Targeted interventions addressing risk factors and healthcare disparities are essential for further reducing asthma burden.

  15. Padhi BK, Khatib MN, Ballal S, Bansal P, Bhopte K, Gaidhane AM, et al.
    BMC Public Health, 2024 Nov 22;24(1):3251.
    PMID: 39578775 DOI: 10.1186/s12889-024-20693-5
    BACKGROUND: People living with HIV (PLWH) are more vulnerable to infectious and non-infectious comorbidities due to chronic inflammation and immune dysfunction. Air pollution is a major global health risk, contributing to millions of deaths annually, primarily from cardiovascular and respiratory diseases. However, the link between air pollution and mortality risk in PLWH is underexplored. This systematic review assesses the association between exposure to pollutants such as particulate matter (PM), nitrogen dioxide (NO2), sulfur dioxide (SO2), ozone (O3), and carbon monoxide (CO) and mortality risk in PLWH.

    METHODS: A systematic search of PubMed, Web of Science, and Embase was conducted for studies published up to August 2024. Eligibility criteria included cohort, case-control, and cross-sectional studies assessing air pollution exposure and mortality in PLWH. Nested-Knowledge software was used for screening and data extraction. The Newcastle-Ottawa Scale was applied for quality assessment. A narrative approach and tabular summarization were used for data synthesis and presentation.

    RESULTS: Nine studies, mostly from China, demonstrated a significant association between long-term exposure to PM1, PM2.5, and PM10 and increased risks of AIDS-related and all-cause mortality in PLWH. Hazard ratios for mortality increased by 2.38-5.13% per unit increase in PM concentrations, with older adults (> 60), females, and those with lower CD4 counts (

  16. Haeuser E, Serfes AL, Cork MA, Yang M, Abbastabar H, Abhilash ES, et al.
    BMC Med, 2022 Dec 19;20(1):488.
    PMID: 36529768 DOI: 10.1186/s12916-022-02639-z
    BACKGROUND: Human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS) is still among the leading causes of disease burden and mortality in sub-Saharan Africa (SSA), and the world is not on track to meet targets set for ending the epidemic by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United Nations Sustainable Development Goals (SDGs). Precise HIV burden information is critical for effective geographic and epidemiological targeting of prevention and treatment interventions. Age- and sex-specific HIV prevalence estimates are widely available at the national level, and region-wide local estimates were recently published for adults overall. We add further dimensionality to previous analyses by estimating HIV prevalence at local scales, stratified into sex-specific 5-year age groups for adults ages 15-59 years across SSA.

    METHODS: We analyzed data from 91 seroprevalence surveys and sentinel surveillance among antenatal care clinic (ANC) attendees using model-based geostatistical methods to produce estimates of HIV prevalence across 43 countries in SSA, from years 2000 to 2018, at a 5 × 5-km resolution and presented among second administrative level (typically districts or counties) units.

    RESULTS: We found substantial variation in HIV prevalence across localities, ages, and sexes that have been masked in earlier analyses. Within-country variation in prevalence in 2018 was a median 3.5 times greater across ages and sexes, compared to for all adults combined. We note large within-district prevalence differences between age groups: for men, 50% of districts displayed at least a 14-fold difference between age groups with the highest and lowest prevalence, and at least a 9-fold difference for women. Prevalence trends also varied over time; between 2000 and 2018, 70% of all districts saw a reduction in prevalence greater than five percentage points in at least one sex and age group. Meanwhile, over 30% of all districts saw at least a five percentage point prevalence increase in one or more sex and age group.

    CONCLUSIONS: As the HIV epidemic persists and evolves in SSA, geographic and demographic shifts in prevention and treatment efforts are necessary. These estimates offer epidemiologically informative detail to better guide more targeted interventions, vital for combating HIV in SSA.

Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links